Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01292733 · ClinicalTrials.gov registry record · Early Phase 1
Cancer Screening Program for Women at High Risk for Developing Ovarian Cancer
A Early Phase 1 study, sponsored by Swedish Medical Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 534
- Enrollment target
NCT01292733: Clinical Trial Early Phase 1 study, sponsored by Swedish Medical Center.
NCT01292733 is a Early Phase 1 study that was terminated before completion, run by Swedish Medical Center. The registered enrollment target is 534 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (908% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01292733, a Early Phase 1 study, was terminated before completion, sponsored by Swedish Medical Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 534 participants
- Enrollment target
Study Summary
The main purpose of this program is to see whether periodically measuring CA-125 (tumor marker) levels in the blood and undergoing transvaginal ultrasounds over time will be effective in the early detection of ovarian cancer.
Interventions
- OTHER Laboratory Tumor Marker Analysis
- OTHER Transvaginal Ultrasound
- OTHER Health Status Questionnaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 534 participants |
| Start Date | 2009-08 |
| Est. Completion | 2015-12 |
| Phase | Early Phase 1 |
Why NCT01292733 stopped before completion
NCT01292733 is an interventional study that assigns participants to a tested intervention. The registered 534 participants enrollment target is mid-sized for trials with a published cap, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (908% higher).
The record links to 0 conditions, and to 3 interventions - of which Laboratory Tumor Marker Analysis is the first listed.
NCT01292733 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01292733 about?
NCT01292733 is a clinical study titled "Cancer Screening Program for Women at High Risk for Developing Ovarian Cancer". The main purpose of this program is to see whether periodically measuring CA-125 (tumor marker) levels in the blood and undergoing transvaginal ultrasounds over time will be effective in the early detection of ovarian cancer.
What is the current status of trial NCT01292733?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 534 participants. The study started on 2009-08. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01292733?
The interventions under investigation include: Laboratory Tumor Marker Analysis (OTHER), Transvaginal Ultrasound (OTHER), Health Status Questionnaire (OTHER).
Who is sponsoring clinical trial NCT01292733?
This trial is sponsored by Swedish Medical Center, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01292733's enrollment target sits among peer trials
534 22nd of 2000 higher than 1,979 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04910685 · 534 participants · Phase 2
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
- NCT06128551 · 534 participants · Phase 1
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- NCT05614739 · 535 participants · Phase 1
FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
- NCT07091617 · 535 participants · NA
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia